Do you, or someone you know, have Alzheimer’s disease?
The MK-7622-012 Trial is evaluating whether an investigational drug, when given with a current standard Alzheimer’s medication, has an effect on abilities affected by the disease, such as understanding, reasoning, and judgment. Individuals may qualify for this trial if they:
- Have a diagnosis of mild to moderate Alzheimer’s disease with a history of mental decline over the past year or more
- Are aged from 55 to 85 years old
- Are already taking donepezil (Aricept™)
Participation will also depend on other requirements.
Trial participants will receive trial medications and trial-related medical care at no charge.
Health insurance is not necessary to participate.
Click here to open the informational pdf in a new window
Or click here to download the pdf